SEC Company Response from Monopar Therapeutics (MNPR) (CIK 0001645469) (MNPR) — Dec 11, 2018
Monopar Therapeutics (MNPR) (CIK 0001645469)
Date: Dec. 11, 2018 · CIK: 0001645469 · Accession: 0001654954-18-013823
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-55866
Referenced dates: December 3, 2018
Letter
Re: Monopar Therapeutics Inc.
Blueprint
December 11, 2018
BY ELECTRONIC SUBMISSION
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
Washington, DC 20549
Form 10-K for the Fiscal Year Ended December 31, 2017, Filed March 26, 2018
File No 000-55866
Ladies and Gentlemen:
Accompanying this letter for filing on behalf of Monopar Therapeutics Inc. (the “Company”) by way of electronic submission is Amendment No. 1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, originally filed on March 26, 2018, Amendment No. 1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, originally filed on May 11, 2018, Amendment No. 1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, originally filed on August 9, 2018, and Amendment No. 1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, originally filed on November 9, 2018. The following addresses the comments of the Staff of the Commission with respect to the Annual and Quarterly Reports listed above, as conveyed in a letter dated December 3, 2018.
Form 10-K for the Fiscal Year Ended December 31, 2017
Exhibits
1.
The suggested revisions have been made to the Annual and Quarterly Reports listed above. Beginning with the 2018 Form 10-K, we will include certification 4(b) and include the reference to the Exchange Act definition of ICFR in the introductory language of certification 4 in all subsequent Forms 10-K and 10-Q.
Please direct any questions or comments regarding the forgoing to the undersigned.
Sincerely,
/s/
Robert K. Rupp
Show Raw Text
CORRESP 1 filename1.htm Blueprint December 11, 2018 BY ELECTRONIC SUBMISSION United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance Washington, DC 20549 Re: Monopar Therapeutics Inc. Form 10-K for the Fiscal Year Ended December 31, 2017, Filed March 26, 2018 File No 000-55866 Ladies and Gentlemen: Accompanying this letter for filing on behalf of Monopar Therapeutics Inc. (the “Company”) by way of electronic submission is Amendment No. 1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, originally filed on March 26, 2018, Amendment No. 1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, originally filed on May 11, 2018, Amendment No. 1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, originally filed on August 9, 2018, and Amendment No. 1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, originally filed on November 9, 2018. The following addresses the comments of the Staff of the Commission with respect to the Annual and Quarterly Reports listed above, as conveyed in a letter dated December 3, 2018. Form 10-K for the Fiscal Year Ended December 31, 2017 Exhibits 1. The suggested revisions have been made to the Annual and Quarterly Reports listed above. Beginning with the 2018 Form 10-K, we will include certification 4(b) and include the reference to the Exchange Act definition of ICFR in the introductory language of certification 4 in all subsequent Forms 10-K and 10-Q. Please direct any questions or comments regarding the forgoing to the undersigned. Sincerely, /s/ Robert K. Rupp Robert K. Rupp